Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

umeclidinium

- PMLiVE

IQWiG knocks back Almirall’s Eklira

Decides added benefit of COPD drug is not proven

- PMLiVE

Novartis’ eye drug Jetrea recommended for EU approval

Set to become first drug treatment for sight-threatening condition vitreomacular traction and macular hole

Boehringer, EFSD offer €2.5m in diabetes research grants

Application accepted up until April 1, 2013

- PMLiVE

FDA fast tracks two new lung cancer drugs

Boehringer’s afatinib and Roche/Astellas’ Tarveca receive accelerated review process

- PMLiVE

AstraZeneca removes R&D and commercial heads

Pascal Soriot's leadership shake-up will see Martin Mackay and Tony Zook leave

- PMLiVE

India could hit Roche and BMS with compulsory licences

Generic versions of Herceptin, Sprycel and Ixempra may reach market before patent expiration

Daiichi Sankyo logo

Daiichi, ArQule cancer drug tivantinib flunks another trial

Fails to meet endpoint in colorectal cancer study

EISAI

Eisai’s farletuzumab fails ovarian cancer trial

Unable to improve progression-free survival

- PMLiVE

GSK and Theravance file COPD combo for EU approval

Filing for LAMA/LABA combination comes shortly after US submission

Novartis building

Novartis parts with Eisai to go it alone with COPD drugs

Ends co-promotion agreement for Onbrez, Seebri and QVA149

- PMLiVE

Nexavar shows promise in thyroid cancer

Potential new indication for Bayer/Onyx drug

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links